ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Arbutus Biopharma Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborations and licenses | $1.48M | $11.49M | $12.60M | $12.87M | $13.35M | $4.30M | $3.92M | $3.81M | $6.97M | $9.70M | $14.27M | $17.31M | 0.8% | -88.9% |
| Non-cash royalty revenue | $869.00K | $1.22M | $1.48M | $1.74M | $2.06M | $2.11M | $2.25M | $2.94M | $3.09M | $3.28M | $3.87M | $4.93M | 0.5% | -57.9% |
By region
From the segment and revenue-disaggregation notes of Arbutus Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.